Palladium‐Catalyzed Asymmetric [4+3] Cycloadditions of Indene‐2‐carbaldehydes with 4‐Vinylbenzoxazinanones Toward Polycyclic 5
<i>H</i>
‐Benzo[
<i>b</i>
]azepines
作者:Xiyuan Zhang、Yanfeng Gao、Zhiwei Miao
DOI:10.1002/adsc.202201199
日期:2023.2.7
AbstractPalladium‐catalyzed asymmetric [4+3] cycloadditions of indene‐2‐carbaldehydes and 4‐vinyl benzoxazinanones proceeded smoothly in the presence of chiral phosphine ligands to give the corresponding functionalized 5H‐benzo[b]azepines (26 examples, 60% to 89% yield, 88:12 to 95.5:4.5 er) under mild conditions.magnified image
DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS
申请人:Bristol-Myers Squibb Company
公开号:EP2880026B1
公开(公告)日:2017-02-22
US9409908B2
申请人:——
公开号:US9409908B2
公开(公告)日:2016-08-09
[EN] DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS<br/>[FR] RÉCEPTEURS P1 DE LA DIHYDROPYRIDONE EN TANT QU'INHIBITEURS DU FACTEUR XIA
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2014022767A1
公开(公告)日:2014-02-06
The present invention provides compounds of Formula (X):(Formula(X), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.